ASSESSMENT OF A NEW CONTACT LAYER * IN THE LOCAL MANAGEMENT OF PEDIATRIC WOUNDS : RESULTS OF AN EUROPEAN CLINICAL STUDY

AUTHORS **A. LETOUZE MD [1], V. VOINCHET MD [2], B. HOCHT MD [3], U. SPECHT MD [4], S. BOHBOT, MD [5],**

[1] Clocheville Hospital, Tours, France [2] North Hospital, Marseille, France
[3] Würzburg Hospital, Germany [4] Saarlouis Hospital, Germany
[5] Laboratoires URGO, franceChenôve

INTRODUCTION

The great majority of the wounds we treat in pediatric plastic surgery and burn units are represented by acute wounds, mainly burns. Therapeutic strategies are quite limited: these wounds are usually treated by dry or impregnated petrolatum gauze. This poster describes the results of a European clinical study (France and Germany) to evaluate the efficacy, tolerance and acceptability of the new ***lipido-colloid contact layer dressing**** *in the healing process of pediatric wounds.*

MATERIALS AND METHODS

A non-comparative multicenter prospective clinical study, using a new ***lipido-colloid contact layer ** (a polyester net impregnated with petrolatum formulation and hydrocolloid particles), was conducted in 16 centers. Subjects were followed for a period of 4 weeks. Subjects consisted of 100 children, ages 1 through 12. Seventy wounds (55 burns and 15 other wounds) were evaluated on a weekly basis (clinical and photographic records).Nursing staff rated the acceptability of the product at every dressing change.*

RESULTS

Baseline characteristics of the sample and wounds are summarized in ***Table 1.***

90 % of the burns and 60% of other wounds healed completely within the 4 weeks. Details of the efficacy results are shown in ***Table 2****.*

Table 1 : Baseline characteristics of patients and wounds

	Burns		Other wounds	
	France (n=55)	Germany (n=22)	France (n=15)	Germany (n=8)
Gender				
Male	**35** (64%)	**9** (41%)	**9** (60%)	**5** (63%)
Female	**20** (36%)	**13** (59%)	**6** (40%)	**3** (37%)
Age				
< 3 years	**38** (69%)	**12** (55%)	**4** (27%)	**1** (13%)
4-6 years	**9** (16%)	**5** (23%)	**2** (13%)	**2** (25%)
> 6 years	**8** (15%)	**5** (23%)	**9** (60%)	**5** (63%)
Wound duration (days)	**3.8**	**1.7**	**15.3**	**13.3**
Mean surface area (cm^2) Min; max	**41.9** (3 ; 188)	**46.0** (1.3 ; 26.7)	**9.1** (2 ; 37)	**8.2** (1.2 ; 28.3)

Table 3 : Pain evaluation

		France	Germany
FACES 3-6 year old children	Smiling	**62.3%**	**58.7%**
	Indifferent	**24.6%**	**28.3%**
	Weeping	**8.2%**	**13.0%**
	Sobbing	**4.9%**	**-**
VAS (mm) Over 6 year old children	Mean	**6 ± 11.3**	**4.8 ± 10.7**
	Min ; Max :	**0 ; 50**	**0 ; 45**

Table 2 : Clinical results

	Burns		Other wounds	
	France (n=55)	Germany (n=22)	France (n=15)	Germany (n=8)
Healed patients	**47**	**22**	**8**	**7**
Mean healing time (days) Min; max	**12.4 ± 5.5** (4 ; 28)	**14.4 ± 6.3** (7 ; 28)	**13.3 ± 4.2** (7 ; 21)	**19.7 ± 4.2** (13 ; 26)
Removal frequency (days) Min; max	**2.7 ± 1.1** (1 ; 8)	**2.6 ± 1.0** (1 ; 7)	**2.8 ± 1.1** (1 ; 7)	**3.1 ± 1.4** (1 ; 8)

Table 4 : Acceptability

	Burns		Other wounds	
	France (n=55)	Germany (n=22)	France (n=15)	Germany (n=8)
Easy *or* ***very easy*** *application*	**88%**	**99%**	**100%**	**94%**
Easy *or* ***very easy*** *removal*	**97%**	**94%**	**100%**	**98%**
None *or* ***slight*** *adherence*	**95%**	**94%**	**100%**	**100%**
None *or* ***slight*** *bleeding*	**95%**	**99%**	**97%**	**100%**

*Pain was evaluated using pain scales adapted to the patient's age (objective pain scale, faces scale and visual analogue scale (VAS)) at each dressing change (****Table 3****). Details of the acceptability are summarized in* ***Table 4.***

Initial injury

After 6 days treatment with ***a new lipido-colloid contact layer****

Initial injury

After 14 days treatment with ***a new lipido-colloid contact layer****

Results ***3 months after injury***

CONCLUSION

This clinical study confirmed the efficacy, the good tolerance and acceptability in children suffering from acute and chronic wounds. This new contact layer dressing represents an appropriate and highly promising alternative to conventional dressings.

** UrgoCell®Silver/Cellosorb®Ag trademark by the Laboratoires URGO (France), in Europe / Restore® Foam Dressing Silver, trademark by Hollister Wound Care LLC in the Northern America*

This study was funded by a grant from Laboratoires URGO, France